Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 26, Issue 4, 2015, Pages 516-522

  Deipolyi, Amy R ^a   Oklu, Rahmi ^b   Al Ansari, Shehab ^b   Zhu, Andrew X ^c   Goyal, Lipika ^c   Ganguli, Suvranu ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; ETHIODIZED OIL; HEMOSTATIC AGENT; MICROSPHERE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASCITES; BILE DUCT DILATATION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHOLECYSTITIS; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG SAFETY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD HEPATIC IMPAIRMENT; MODEL FOR END STAGE LIVER DISEASE SCORE; MODERATE HEPATIC IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADMINISTRATION AND DOSAGE; CARCINOMA, HEPATOCELLULAR; DELAYED RELEASE FORMULATION; DOSE RESPONSE; LIVER NEOPLASMS; PARTICLE SIZE; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHIODIZED OIL; FEMALE; HEMOSTATICS; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PARTICLE SIZE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925400155     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2014.12.020     Document Type: Article

References (18)

1. A. Forner, M.E. Reig, C.R. de Lope, and J. Bruix Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
2. I. Sakamoto, N. Aso, and K. Nagaoki Complications associated with transcatheter arterial embolization for hepatic tumors Radiographics 18 1998 605 619
3. J.W. Chung, J.H. Park, and J.K. Han Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization Radiology 198 1996 33 40
4. A.L. Lewis, R.R. Taylor, B. Hall, M.V. Gonzalez, S.L. Willis, and P.W. Stratford Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization J Vasc Interv Radiol 17 2006 1335 1343
5. K. Hong, A. Khwaja, E. Liapi, M.S. Torbenson, C.S. Georgiades, and J.F. Geschwind New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer Clin Cancer Res 12 2006 2563 2567
6. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
7. T.J. Vogl, J. Lammer, and R. Lencioni Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial AJR Am J Roentgenol 197 2011 W562 W570
8. S.P. Kalva, M. Pectasides, and R. Liu Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma Cardiovasc Intervent Radiol 37 2014 381 387
9. S.P. Kalva, M. Pectasides, K. Yeddula, S. Ganguli, L.S. Blaszkowsky, and A.X. Zhu Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma J Vasc Interv Radiol 24 2013 257 265
10. S.A. Padia, G. Shivaram, and S. Bastawrous Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles J Vasc Interv Radiol 24 2013 301 306
11. K.H. Lee, E. Liapi, and J.A. Vossen Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy J Vasc Interv Radiol 19 2008 1490 1496
12. U.S. Department of Health and Human Services, National Institutes of Health, and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.3. 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed September 2014
13. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
14. J. Namur, M. Wassef, J.M. Millot, A.L. Lewis, M. Manfait, and A. Laurent Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model J Vasc Interv Radiol 21 2010 259 267
15. Y. Nakanuma, M. Hoso, T. Sanzen, and M. Sasaki Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply Microsc Res Tech 38 1997 552 570
16. U. Wagnetz, J. Jaskolka, P. Yang, and K.S. Jhaveri Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome J Comput Assist Tomogr 34 2010 348 353
17. T. Bilhim, J.M. Pisco, M. Duarte, and A.G. Oliveira Polyvinyl alcohol particle size for uterine artery embolization: a prospective randomized study of initial use of 350-500 mum particles versus initial use of 500-700 mum particles J Vasc Interv Radiol 22 2011 21 27
18. J.H. Shim, H.C. Lee, and S.O. Kim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718